All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Kahr Medical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

ASCO 2020

Participation Not Confirmed

Update your events

KAHR Medical Raises $18 Million in Private Funding Round

Contact the Supplier

Lead Product(s): DSP107,Atezolizumab

Therapeutic Area: Oncology

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: Flerie Invest AB

Deal Size: $18.0 million Upfront Cash: Undisclosed

Deal Type: Funding February 25, 2020

Details:

Proceeds will be used for advancing the Company's next generation immuno-oncology drug candidates including the clinical development of the Company's lead product, DSP107, an anti-CD47 therapy.